Advances in the application of direct-acting antivirals in patients with hepatitis C cirrhosis
Chronic hepatitis C virus(HCV)infection can lead to liver cirrhosis,and complications after liver cirrhosis,including hepatocellular carcinoma(HCC),are the leading causes of death in patients with chronic liver diseases.Antiviral therapy can help to realize sustained virologic response,improve hepatitis and liver fibrosis,and delay disease progression.The safety and efficacy of direct-acting antivirals(DAAs)have been confirmed in patients with HCV-related liver cirrhosis,and whether DAAs can improve the complications and prognosis of patients with liver cirrhosis has gradually become a research hotspot.Related data are mainly reported by foreign scholars,and since DAAs have not been marketed in China for a long time,there is still a lack of mid-and long-term data.This article reviews the latest studies on the application of DAAs in patients with HCV-related liver cirrhosis and the impact of DAAs on clinical prognosis.
国家科技期刊平台
NSTL
万方数据
